KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Notes Payables: 2016-2024

Historic Notes Payables for Emergent BioSolutions (EBS) over the last 5 years, with Sep 2024 value amounting to $800,000.

  • Emergent BioSolutions' Notes Payables fell 99.81% to $800,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $800,000, marking a year-over-year decrease of 99.81%. This contributed to the annual value of $413.7 million for FY2023, which is 56.78% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Notes Payables of $800,000 as of Q3 2024, which was down 99.81% from $415.2 million recorded in Q2 2024.
  • Emergent BioSolutions' Notes Payables' 5-year high stood at $957.3 million during Q4 2022, with a 5-year trough of $800,000 in Q3 2024.
  • Over the past 3 years, Emergent BioSolutions' median Notes Payables value was $413.7 million (recorded in 2023), while the average stood at $377.3 million.
  • Its Notes Payables has fluctuated over the past 5 years, first spiked by 2,929.43% in 2022, then plummeted by 99.81% in 2024.
  • Over the past 5 years, Emergent BioSolutions' Notes Payables (Quarterly) stood at $33.8 million in 2020, then declined by 6.51% to $31.6 million in 2021, then soared by 2,929.43% to $957.3 million in 2022, then plummeted by 56.78% to $413.7 million in 2023, then plummeted by 99.81% to $800,000 in 2024.
  • Its Notes Payables stands at $800,000 for Q3 2024, versus $415.2 million for Q2 2024 and $459.2 million for Q1 2024.